Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare cancer: tarlatamab takes on chemo in phase 3 trial

NCT ID NCT06937905

Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether the drug tarlatamab can help people with advanced neuroendocrine carcinoma live longer compared to standard chemotherapy. The study plans to enroll 129 participants who have already received prior treatment. Tarlatamab is given as an infusion every two weeks, while the chemotherapy options vary based on tumor type.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tarlatamab
What this could lead to
If it works, this could offer a new treatment option for people with advanced neuroendocrine carcinoma who have already tried other therapies.
What could go wrong
This is a Phase 3 trial, but it is still early to know if tarlatamab will work better than chemotherapy. Side effects, including immune reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 129 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed Informed consent: * Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. * Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing 2. Age ≥ 18 years. 3. WHO Performance status 0 - 1. 4. Life expectancy \> 12 weeks. 5. Histologically proven and centrally confirmed poorly differentiated neuroendocrine carcinoma (NEC): large cells for lung NEC (WHO 2015 classification), and large and small cells for extra-gastroenteropancreatic (assessed on archived tissue, with possible pre-screening during first-line). 6. Expression of DLL3 in at least 1% of tumor cells (assessed on archived tissue, with possible pre-screening during first-line) 7. Tumor progression following one platinum based line of therapy. 8. Unresectable locally advanced or metastatic stage. 9. At least one measurable target lesion according to RECIST v1.1 per investigator assessment. The radiological assessment has to be done within the timelines indicated. 10. Adequate organ function: creatinine clearance \> 50 mL/min, Neutrophils count ≥ 1500/mm3; Platelets \> 100 000/mm3 ; Hemoglobin \> 9 g/dL; AST and ALT \< 3 x ULN (upper limit of normal) with total bilirubin ≤ 2 × ULN except subjects with documented Gilbert's syndrome or liver metastasis, who must have AST and ALT ≤ 5 x ULN and a baseline total bilirubin ≤ 3.0 mg/dL. 11. Full recovery from all toxicities associated with prior treatment, to acceptable baseline status, or a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia or vitiligo. 12. Availability of tumor material for central review processes and translational research projects. 13. Absence of any unstable systemic disease and any psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule. 14. Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 7 months after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. They must also refrain from egg cell donation for 7 months after the final dose of investigational product. 15. Men who are sexually active with women of childbearing potential will be instructed to adhere to contraception for a period of 6 months after the last dose of treatment. 16. Patient covered by a national health insurance. Exclusion Criteria: 1. Well-differentiated neuroendocrine tumor (NET G1, G2 and G3 according to digestive WHO 2017 classification or typical/atypical carcinoid tumor according to lung WHO 2015 classification) 2. Previous treatment targeting DLL3 3. More than one line of systemic therapy in the metastatic setting. Chemotherapy for non-metastatic stage is not considered as first-line if there is a time interval of at least 6 months between the last dose of chemotherapy for non-metastatic stage and the initiation of first-line chemotherapy for metastatic/recurrent disease. 4. Small cell lung NEC (except as a minor \<30% component in mixed tumors) 5. Known EGFR activating mutation or ALK or ROS1 rearrangement for lung NEC 6. Untreated or symptomatic central nervous system (CNS) metastases: * Subjects with asymptomatic CNS metastases are eligible if clinically stable for at least 4 weeks and do not require intervention (including use of corticosteroids). * Subjects with treated brain metastases are eligible provided the following criteria are met: * Subject is asymptomatic from brain metastases * Whole brain radiation or surgery was completed at least 2 weeks prior to first dose of study treatment (stereotactic radiosurgery completed at least 7 days prior to first dose of study treatment) * Any CNS disease is clinically stable, subject is off steroids for CNS disease for at least 5 days (unless steroids are indicated for a reason unrelated to CNS disease), and subject is off or on stable doses of anti-epileptic drugs at least 14 days prior to first dose of study treatment 7. Leptomeningeal metastasis 8. Patients with a recent history of other malignancies except adequately treated non-melanoma skin cancer, and curatively treated in-situ cancer. Patients with history of solid tumors, including adenocarcinoma, treated in a curative way with or without chemotherapy and without any evidence of disease \>2 years before randomisation can be included as well. 9. Major surgery within 28 days prior to initiation of study treatment. 10. Myocardial infarction and/or symptomatic congestive heart failure (New York Head Association class \> class II) within 12 months prior to initiation of study treatment. 11. History of arterial thrombosis (e.g. stroke or transient ischemic attack) within 12 months prior to initiation of study treatment. 12. Symptoms and/or clinical and/or radiological signs suggestive of uncontrolled and/or acute active systemic infection within 7 days prior to first administration ofstudy treatment. Patient with active infection requiring parenteral antibiotic therapy. Upon completion of parental antibiotic therapy and resolution of symptoms, the patient may be considered eligible under the infection criterion. 13. Known sensitivity and/or immediate hypersensitivity to any component of study treatment. 14. History of primary immunodeficiency, history of organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy. 15. Patients with immune pneumonitis, pituitary or thyroid disorders, or pancreatitis under treatment with immuno-oncology agents. 16. Patients reporting infusion-related reactions or severe, life-threatening or recurrent immune-mediated adverse events (grade 2 or higher), including events leading to permanent discontinuation of immuno-oncology agents. 17. Presence of an indwelling line or drain (including the following: percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, peritoneal drain or catheter, pericardial drain or catheter, drain catheter or thoracic drain for pleural fluid collection). 18. Patient with a diagnosis of immunodeficiency or undergoing systemic corticotherapy or any other form of immunosuppressive therapy within 7 days prior to administration of the first dose of study treatment. 19. Known acute or chronic B or C hepatitis by serological evaluation. Patients with serological sequellae of hepatitis (antibodies test serologically positive for virus) without hepatitis could be included. 20. Known Human immunodeficiency virus infection 21. Patients who are pregnant or breast-feeding, or planning to become pregnant or breast-feed during the trial and within 7 months after the last dose of study treatment. 22. Male not wishing to abstain from sperm donation during the trial and within 6 months of the last study treatment. 23. Vaccination with live or attenuated virus vaccines is not permitted during the 28 days prior to administration of the first dose of treatment, and for the duration of the study. Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be avoided during selection, at least 14 days before the first day of treatment. Live, non-replicating smallpox vaccines (such as Jynneos) against monkeypox infection are permitted during the study (except during cycle 1) in accordance with the center's standard of care and internal recommendations. 24. Active autoimmune disease requiring systemic therapy (except replacement therapy) within the last 2 years or any other disease requiring immunosuppressive therapy during the study. 25. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine; carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine; carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    40 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Angers - CHU

    RECRUITING

    Angers, France

    Contact Email: •••••@•••••

  • Avignon - CH

    RECRUITING

    Avignon, France

    Contact Email: •••••@•••••

  • Besançon - CHU

    RECRUITING

    Besançon, France

    Contact Email: •••••@•••••

  • Bordeaux - CHU

    RECRUITING

    Pessac, France

  • Bordeaux - CHU

    RECRUITING

    Pessac, France

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Boulogne - Ambroise Paré

    RECRUITING

    Boulogne, France

  • Caen - CHU

    RECRUITING

    Caen, France

  • Caen - CHU

    RECRUITING

    Caen, France

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Dijon - CHU Bocage

    RECRUITING

    Dijon, France

    Contact Email: •••••@•••••

  • Dijon - Centre Georges-François Leclerc

    RECRUITING

    Dijon, France

    Contact Email: •••••@•••••

  • Grenoble - CHU

    RECRUITING

    Grenoble, France

    Contact Email: •••••@•••••

  • Le Mans - CHG

    RECRUITING

    Le Mans, France

    Contact Email: •••••@•••••

  • Lille - Centre Oscar Lambret

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

  • Limoges - CHU

    RECRUITING

    Limoges, France

  • Limoges - CHU

    RECRUITING

    Limoges, France

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Lyon - Centre Léon Bérard

    RECRUITING

    Lyon, France

    Contact Email: •••••@•••••

  • Lyon - HCL

    RECRUITING

    Pierre-Bénite, France

    Contact Email: •••••@•••••

  • Lyon - Hôpital Edouard Herriot

    RECRUITING

    Lyon, France

    Contact Email: •••••@•••••

  • Lyon - Hôpital Privé Jean Mermoz

    RECRUITING

    Lyon, France

    Contact Email: •••••@•••••

  • Marseille - APHM

    RECRUITING

    Marseille, France

    Contact Email: •••••@•••••

  • Marseille - Institut Paoli-Calmettes

    RECRUITING

    Marseille, France

    Contact Email: •••••@•••••

  • Montpellier - CHU

    RECRUITING

    Montpellier, France

    Contact Email: •••••@•••••

  • Nantes - Hôpital Laennec

    RECRUITING

    Saint-Herblain, France

    Contact Email: •••••@•••••

  • Nantes - Institut de Cancérologie de l'Ouest

    RECRUITING

    Saint-Herblain, France

    Contact Email: •••••@•••••

  • Nice - Centre Antoine Lacassagne

    RECRUITING

    Nice, France

    Contact Email: •••••@•••••

  • Paris - Curie

    RECRUITING

    Paris, France

  • Paris - Hôpital Cochin

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Paris - Saint-Antoine

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Paris - Tenon

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Poitiers - CHU

    RECRUITING

    Poitiers, France

    Contact Email: •••••@•••••

  • Reims - CHU

    RECRUITING

    Reims, France

    Contact Email: •••••@•••••

  • Rennes - CHU

    RECRUITING

    Rennes, France

    Contact Email: •••••@•••••

  • Rouen - CHU

    RECRUITING

    Rouen, France

    Contact Email: •••••@•••••

  • Strasbourg - Nouvel Hôpital Civil

    RECRUITING

    Strasbourg, France

    Contact Email: •••••@•••••

  • Toulon - CHI

    RECRUITING

    Toulon, France

    Contact Email: •••••@•••••

  • Toulouse - CHU

    RECRUITING

    Toulouse, France

    Contact Email: •••••@•••••

  • Tours - CHU

    RECRUITING

    Chambray-lès-Tours, France

    Contact Email: •••••@•••••

  • Tours - CHU

    RECRUITING

    Tours, France

    Contact Email: •••••@•••••

  • Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine

    RECRUITING

    Vandœuvre-lès-Nancy, France

    Contact Email: •••••@•••••

  • Villefranche sur Saône - CH

    RECRUITING

    Villefranche-sur-Saône, France

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.